NCT03385135

Allopurinol and Endothelial Function in Diabetic CAD Patients

Impact of ALLopurInol on Endothelial fuNCtion in diabEtic Patients Affected With Coronary Artery Disease

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: University Tunis El Manar · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. After initial screening, subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with a 4-weekly check on hematology and biochemistry

Conditions

• Diabetes Mellitus
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Allopurinol	300 mg for 4 weeks then 600 mg for 4 weeks in the active group

Timeline

• Start date: 2017-12-01
• Primary completion: 2018-03-01
• Completion: 2018-06-01
• First posted: 2017-12-28
• Last updated: 2017-12-28

Locations

1 site across 1 country: Tunisia